Oral Teriflunomide in relapsing MS study reported

Aubagio is an oral treatment approved for MS.
Post Reply
User avatar
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm

Oral Teriflunomide in relapsing MS study reported

Post by MSUK » Tue Dec 20, 2011 12:04 am


Genzyme, a Sanofi company , today reported top-line results from TENERE, a Phase III clinical trial comparing the effectiveness, safety and tolerability of once-daily oral teriflunomide to interferon beta-1a (Rebif(R)), an approved injectable therapy, in people with relapsing forms of multiple sclerosis (RMS).

The TENERE trial, which included 324 patients, is the second completed study of five efficacy studies of teriflunomide in MS, making the clinical program one of the largest and broadest of any multiple sclerosis agent under development.....Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/

User avatar
Family Elder
Posts: 3367
Joined: Wed Jul 27, 2005 2:00 pm
Location: Sydney, Australia

Re: Oral Teriflunomide in relapsing MS study reported

Post by CureOrBust » Tue Dec 20, 2011 4:23 am

Not looking any better than rebif on effectiveness.
No statistical superiority was observed between the Rebif and teriflunomide arms (7mg and 14mg) on risk of treatment failure, the primary composite endpoint of the study. Risk of treatment failure was defined as the occurrence of a confirmed relapse or permanent treatment discontinuation for any cause, whichever came first. In the study, 48.6 percent of patients receiving 7mg of oral teriflunomide (n=109) and 37.8 percent of patients receiving 14 mg of oral teriflunomide (n=111) reached the primary endpoint, versus 42.3 percent of patients receiving interferon beta 1-a (n=104).
But they appear to be taking it to the next step.

Post Reply
  • Similar Topics
    Last post